triamcinolone acetonide + tacrolimus

Triamcinolone acetonide + tacrolimus is a topical combination therapy primarily investigated and utilized for the treatment of vitiligo, particularly in stable or refractory cases. Triamcinolone acetonide is a synthetic glucocorticoid with potent anti-inflammatory and immunosuppressive properties; it acts as an agonist at the glucocorticoid receptor to suppress the production of inflammatory cytokines and modulate immune cell activity. Tacrolimus is a calcineurin inhibitor that binds to the intracellular protein FKBP12, forming a complex that inhibits the phosphatase activity of calcineurin. This inhibition prevents the dephosphorylation of the nuclear factor of activated T-cells (NFAT), thereby blocking T-cell activation and the subsequent autoimmune destruction of melanocytes. The combination is designed to provide synergistic efficacy in promoting repigmentation while potentially minimizing the side effects associated with long-term corticosteroid monotherapy. Research into this specific formulation has been notably conducted by institutions such as the Shanghai 6th People's Hospital.

Other names

triamcinolone acetonide and tacrolimus ointment